GlassScriptPhysician profile
Holly D Steely
NPI 1356871560
$7,409.59
in general payments reported to CMS, 2019-2025
13 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $486 · 2022: $357 · 2023: $4,953 · 2024: $1,247 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,925 · Food and Beverage: $2,240 · Travel and Lodging: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,925.00 |
| Food and Beverage | $2,239.62 |
| Travel and Lodging | $1,402.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,054.16 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $524.32 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $499.48 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $361.47 | 2024 | Auvelity |
| Neurocrine Biosciences, INC. | $248.66 | 2024 | Ingrezza |
| Alkermes, INC. | $216.53 | 2021-2023 | Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $144.72 | 2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $138.48 | 2022-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $126.23 | 2025 | Cobenfy |
| Redhill Biopharma INC. | $41.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.92 | 2021 | |
| Indivior INC. | $16.19 | 2022 | |
| Uswm, LLC | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Steely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.